Clinical study on acupoint thread embedding combined with Wenshen Bugu Formula for treatment of aromatase inhibitor associated musculoskeletal symptoms in patients of postmenopausal breast cancer
Objective:To observe the clinical efficacy of acupoint thread embedding(ATE)combined with Wenshen Bugu Formula for the treatment of aromatase inhibitor associated musculoskeletal symptoms(AIMSS)in postmenopausal women with breast cancer.Methods:A randomized controlled trial design was conducted.A total of 128 postmenopausal breast cancer patients with AIMSS were randomly divided into ATE combined with Chinese medicine group and Chinese medicine group,64 cases in each group.The patients in both groups were treated with Wenshen Bugu Formula decoction orally,and the patients in the ATE combined with Chinese medicine group were treated with ATE based on above.The treatment course of two groups was 12 weeks,and the patients were followed up for 12 weeks after the treatment course.Before treatment and at the 6th,12th,18th,and 24th weeks of treatment,the scores of Brief Pain Inventory-Short Form(BPI-SF)and Functional Assessment of Cancer Therapy-Breast(FACT-B)in both groups were assessed.Before treatment and at the 12th and 24th weeks of treatment,the Morisky Medication Adherence Scale(MMAS-8)scores of the two groups were evaluated.Results:During the research,three cases were eliminated and 4 cases were shed off in the ATE combined with Chinese medicine group,and 1 case was eliminated and 6 cases were shed off in the Chinese medicine group.Finally,61 cases in the ATE combined with Chinese medicine group and 63 cases in the Chinese medicine group were included in the modified intention-to-treat(mITT)analysis.①After treatment,the scores of the Brief Pain Inventory-Worst Pain(BPI-WP),average pain,pain severity,and pain interference in both groups were significantly decreased compared with those before treatment(P<0.01).Compared with the Chinese medicine group,at the 12th,18th,and 24th weeks of treatment,the BPI-WP scores of the ATE combined with Chinese medicine group were significantly decreased(P<0.05),at the 12th and 18th weeks of treatment,the average pain scores and pain severity scores of the ATE combined with Chinese medicine group were significantly decreased(P<0.05),and at the 12th week of treatment,the pain interference scores of the ATE combined with Chinese medicine group were significantly decreased(P<0.05).②At the 6th,12th,18th,and 24th weeks of treatment,the FACT-B scores of both groups were significantly increased compared with those before treatment(P<0.01),and the score of the ATE combined with Chinese medicine group was higher than that of the Chinese medicine group(P<0.05).③At the 12th and 24th weeks of treatment,the MMAS-8 scores in both groups were significantly increased compared with those before treatment(P<0.01).However,no statistically significant difference on the score was observed between the two groups(P>0.05).Conclusion:Compared with Chinese medicine treatment alone,the traditional Chinese medicine comprehensive therapy of ATE combined with Wenshen Bugu Formula can more effectively alleviate joint pain for postmenopausal breast cancer patients with AIMSS,and enhance the quality of life,with persistent efficacy,which is worthy of clinical promotion.
aromatase inhibitor associated musculoskeletal symptomspostmenopausal breast canceracupoint thread embeddingWenshen Bugu Formulatraditional Chinese medicine therapy
NETL
NSTL
万方数据
